DMTX Dimension Therapeutics Inc.

5.98
-0.03  -0%
Previous Close 6.00
Open 6.00
Price To book 4.18
Market Cap 150624689
Shares 25,209,153
Volume 146,712
Short Ratio 0.58
Av. Daily Volume 262,195

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initial data due late 2017.
DTX301
Ornithine Transcarbamylase (OTC) Deficiency
Phase 1/2 initial data released January 31, 2017. Announced May 10, 2017 that program will be discontinued.
DTX101
hemophilia B

Latest News

  1. SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of Dimension Therapeutics, Inc. - DMTX
  2. WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders
  3. SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation Of Dimension Therapeutics, Inc. - DMTX
  4. Harwood Feffer LLP Announces Investigation of Dimension Therapeutics, Inc.
  5. ​After bidding war, North Bay drug maker snags gene therapy company for $151 million
  6. ​After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout
  7. Dimension (DMTX) Alert: Johnson Fistel Investigates Proposed Sale of Dimension Therapeutics, Inc.; Are Shareholders Getting a Fair Price?
  8. Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers
  9. Ultragenyx to Acquire Dimension Therapeutics
  10. RegenxBio declines to push forward on planned acquisition
  11. REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics
  12. Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”
  13. Today's Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis Oncology
  14. Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
  15. Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx
  16. UPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bid
  17. Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers
  18. Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash
  19. OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors